高风险区域选择性淋巴结照射优于累及野放疗治疗局限期小细胞肺癌:倾向性评分匹配回顾性研究
本研究回顾性分析2018年1月至2023年6月接受根治性同步减量放疗和化疗(联合或不联合免疫治疗)的局限期小细胞肺癌(LS-SCLC)患者540例,按靶区勾画方式分为选择性淋巴结照射(ENI)组196例和累及野放疗(IFRT)组344例,经倾向性评分匹配后每组183例。结果显示ENI组中位总生存期(OS)、无进展生存期(PFS)和无远处转移生存期(DMFS)均显著优于IFRT组,且放射性肺炎和食管炎发生率无显著差异,ENI组淋巴结野外复发(ENF)累积发生率显著更低。
要点
- ENI组中位OS为37.7个月,IFRT组为26.7个月(P=0.007)。
- ENI组中位PFS为12.2个月,IFRT组为8.7个月(P=0.006)。
- 两组放射性肺炎和食管炎发生率相似,ENI未显著增加不良反应。
核心结论
- 与IFRT相比,ENI未显著增加不良反应发生率,同时有效延长OS、PFS和DMFS,并降低ENF风险。
研究设计与样本
- 真实世界回顾性研究,纳入2018年1月至2023年6月接受根治性同步减量放疗和化疗(联合或不联合免疫治疗)的LS-SCLC患者540例,按靶区勾画方式分为ENI组(196例,36.3%)和IFRT组(344例,63.7%),采用倾向性评分匹配平衡组间可观察的潜在混杂因素,匹配后每组183例。
主要发现
- 匹配后IFRT组中位OS为26.7个月,ENI组为37.7个月(P=0.007)。
- 匹配后IFRT组中位PFS为8.7个月,ENI组为12.2个月(P=0.006)。
- 匹配后IFRT组中位DMFS为12.3个月,ENI组为28.6个月(P=0.004)。
- 两组放射性肺炎发生率相似(P=0.646),食管炎发生率相似(P=0.493)。
- IFRT组ENF的1年累积发生率为13.9%(95% CI 8.8–18.9%),ENI组为2.7%(95% CI 0.4–5.1%)(Gray's p < 0.001)。
临床怎么用
- 对于接受根治性同步减量放疗和化疗的LS-SCLC患者,采用ENI照射高风险淋巴结区域可能改善生存并降低ENF风险,且不显著增加放射性肺炎和食管炎。
局限性
- 本研究为单中心回顾性研究,尽管采用倾向性评分匹配,仍可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Whether to omit elective nodal irradiation (ENI) in thoracic radiotherapy for limited-stage small cell lung cancer (LS-SCLC) remains controversial. The purpose of this study was to compare the efficacy and safety of ENI in high-risk lymph node regions compared to involved field radiotherapy (IFRT). MATERIALS AND METHODS: We conducted a real-world retrospective study of LS-SCLC who received radical simultaneous dose-reduction radiotherapy (SDR-RT) and chemotherapy with or without immunotherapy from January 2018 to June 2023. Patients were divided into two groups based on the target volume delineation method: the ENI group and the IFRT group. Propensity score matching (PSM) was applied to balance the observable potential confounding factors between the two groups. The primary endpoints were overall survival (OS). RESULTS: A total of 540 eligible patients were enrolled, of whom 196 (36.3%) received ENI and 344 (63.7%) received IFRT. After PSM, the clinical characteristics of both groups were balanced, including 183 patients each. The median OS was 26.7 months in the IFRT group versus 37.7 months in the ENI group (P = 0.007). The median PFS was 8.7 months in the IFRT group versus 12.2 months in the ENI group (P = 0.006). The median DMFS was 12.3 months and 28.6 months in the two groups (P = 0.004), respectively. The incidence of radiation pneumonia (P = 0.646) and esophagitis (P = 0.493) were similar between the two groups. The 1-year cumulative incidence rate of ENF was 13.9% (95% CI 8.8–18.9%) in the IFRT group and 2.7% (0.4–5.1%) in the ENI group (Gray’s p < 0.001). CONCLUSION: ENI did not significantly increase the rate of adverse reactions compared to IFRT, while effectively prolonging OS, PFS, and DMFS, and reducing the risk of ENF in patients with LS-SCLC. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Zhang Z, Yan M, Gao J, et al. Elective nodal irradiation of high-risk regions is superior to involved field radiotherapy for limited-stage small cell lung cancer: a propensity score-matched retrospective study. Radiat Oncol. 2026. PMID: 42050661. doi:10.1186/s13014-026-02845-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。